Moreover, prognosis following the development of brain metastases is also associated with breast cancer subtype where survival following central nervous system recurrence is 3 to 4 months for women with triple-negative disease compared to 9 and 15 months for HER2-positive and endocrine-sensitive counterparts, respectively [5]. This evidence concerns the gene ERBB2 and breast carcinoma.